BPC-157 Benefits and Side Effects: Research Data
What the animal models report, what the five small human studies measured, what FDA found on safety in 2026, and where BPC-157 stands with regulators.
Update History ▾
Research-use-only framing applied throughout in line with Remy editorial standards.
The claimed BPC-157 benefits (faster tissue repair, gut health, joint health and pain reduction) come almost entirely from animal models. In people there are five small studies and no rigorous clinical trial showing that it works. FDA’s July 2026 review concluded that the data do not support its use for ulcerative colitis and that there is insufficient clinical safety information to characterise its safety profile.[1] A 2026 systematic review rated the human evidence as very low certainty.[2]
Reported side effects in people are few because so few people have been studied. FDA found three adverse-event reports, each one involving injectable BPC-157 and none clearly attributable to it.[1] Its potential risks are mostly unknowns: immune reactions, impurities in unregulated products, and long-term effects that no study has measured. BPC-157 is not FDA-approved, and Remy Research supplies it for in-vitro laboratory research only.
What Is BPC-157?
BPC-157, short for body protection compound 157, is a synthetic peptide of 15 amino acids. Its sequence is a fragment of a larger protein found in human gastric juice, which is why most of its early research came from gut-injury models.[3] It is a short chain compared with protein medicines and is made by chemical synthesis, not extracted from the stomach.
It is not a dietary supplement, is not intended for human use when sold for research, and is not an approved medicine anywhere: FDA reports no approved BPC-157 product in any country.[1] Everything below separates what was seen in animal models from what has been measured in people, because most online lists of “BPC 157 benefits” blur the two.
How BPC-157 Is Thought to Work: Angiogenesis and Reduced Inflammation
Researchers propose several overlapping mechanisms at the cellular level, and no specific receptors for it have been identified. In cell and animal studies BPC-157 increased VEGFR2 receptor signalling and blood vessel formation (angiogenesis), which is the basis for claims that it increases blood flow to injured tissue.[4] In tendon cells it supported cell outgrowth, survival and migration.[5] FDA’s review lists the same hypotheses: up-regulation of growth factors and their receptors, suppression of inflammatory factors, which would mean reduced inflammation at the injury, blood vessel growth and nitric oxide signalling.[1] These anti-inflammatory and repair signals are what “BPC 157 benefits” usually refers to.
None of these mechanisms has been confirmed in human tissue in a controlled study. They explain why the peptide is studied; they do not show that it delivers a benefit in people.
Potential Benefits in Animal Models
The vast majority of BPC-157 research studies use rats and mice, and most come from one group of laboratories in Croatia.[3][6] The main areas are below. Promising results in these models are the reason for interest, not evidence of medical use.
| Claimed benefit | What was reported | Evidence type |
|---|---|---|
| Gut health | Protection of the stomach and bowel lining in injury models | Animal |
| Tendon injuries | More outgrowth, survival and migration of tendon cells | Cell culture (rat) |
| Blood vessel growth | More new blood vessels and VEGFR2 signalling | Animal, cell culture |
| Wound healing | Apparent healing effects in several tissue types | Animal |
| Knee pain | Self-reported relief after joint injection | Uncontrolled human |
| Ulcerative colitis | One small trial; FDA found it does not support use | Human, abstract only |
Gut Health, Gut Healing and the Digestive System
Gastrointestinal protection is the oldest strand of the work, covering stomach ulcers, fistulas and inflammatory bowel models along the gastrointestinal tract of rodents.[3] Gut healing in these models is the origin of the “gut health” claim.
Musculoskeletal Injuries, Muscle Repair and Injury Recovery
Tendon tears, ligament injuries and muscle repair are the main orthopedic conditions studied, along with other soft tissue injuries. In explants and fibroblasts from rat tendons, BPC-157 increased cell outgrowth, survival and migration.[5]
Wound Healing and Tissue Repair
FDA’s review describes the apparent wound-healing properties of BPC-157 in different tissues, in animal models, as the main hypothesis behind this work.[1] No study has measured wound healing or tissue repair in people with a control group. A 2026 scoping review of six peptides used in sports medicine found that 67% of the publications it identified used animal models and judged the claimed musculoskeletal benefits unsubstantiated by human trials.[6] Claims that BPC-157 can accelerate recovery from a sports injury or repair damaged tissue in people therefore rest on preclinical studies, not on tissue healing measured in patients.
Blood Vessel Growth, Angiogenesis and Blood Flow
Rodent work on ischemia-reperfusion injury, where blood flow is cut and restored, reports protective effects across various tissues. A 2026 critical review of that work found it consistent in direction but limited by small studies and by the concentration of the literature in few laboratories.[7]
What Human Clinical Trials Show
FDA’s July 2026 briefing lists five human studies.[1] Two were placebo-controlled studies given by enema and reported only as conference abstracts: a phase 1 tolerability study in 32 healthy volunteers and a 2005 trial in people with mild-to-moderate ulcerative colitis. The other three are small uncontrolled pilot reports:
- Chronic knee pain, 2021. A retrospective chart review asked 16 patients by phone about knee pain after a joint injection of BPC-157, alone or with thymosin beta-4. There was no control group and no validated outcome measure.[8]
- Interstitial cystitis, 2024. A single-arm pilot in 12 women reported self-rated symptom improvement, again without a control arm.[9]
- Intravenous safety pilot, 2025. Two adults received BPC-157 by infusion; the heart, liver, kidney, thyroid and glucose markers tested did not change.[10]
No human clinical trial has shown efficacy. FDA concluded that the data do not support BPC-157 for ulcerative colitis, the one use it reviewed.[1] A 2026 systematic review found three eligible human studies with 30 participants in total, judged all of poor quality, rated the certainty of evidence as very low, and concluded that BPC-157 should not be used clinically in orthopaedic or regenerative medicine outside ethically approved, high-quality trials.[2] A controlled trial after rotator cuff surgery is registered at the University of Arkansas but had not started recruiting when checked on October 27, 2026.[11]
Potential Risks, Side Effects and Safety Concerns
Because so few people have been studied, there is no reliable list of potential side effects, and no data on how BPC-157 interacts with other medications. What has been published:
- Adverse-event reports. FDA’s search found three reports, all involving injectable products: nine days of redness and swelling at the injection site in a woman also using injectable thymosin; shortness of breath leading to an emergency visit, with no further detail; and diffuse skin and gum darkening that returned on re-exposure to a product combining BPC-157 with TB-500. In each case the role of BPC-157 could not be separated from the other product or the missing information.[1]
- Immunogenicity and impurities. FDA said it cannot rule out immune reactions caused by impurities and peptide aggregates, and judged that a 15-amino-acid peptide given by injection or nasally may pose a significant immunogenicity risk, one of the significant risks it weighed.[1]
- Long-term effects. FDA found no carcinogenicity studies.[1] Because the proposed mechanisms include growth factors and new blood vessels, the absence of long-term data is a major concern for medical professionals reviewing it.
- Animal toxicology. Single- and repeat-dose studies in mice, rats, rabbits and dogs reported no serious toxicity.[12] In rats and dogs the intact peptide had a half-life under 30 minutes.[13]
- Product quality in the UAE. UAE doctors interviewed by Gulf News in 2026 described a wellness trend in which peptide-based medicine such as GLP-1 drugs has raised interest in unapproved peptides, and warned that many peptides sold online are not pharmaceutical grade, and named contaminated or mislabelled products and combining multiple peptides without guidance among the main risks.[14] One of FDA’s three adverse-event reports involved a product combining BPC-157 with TB-500.[1]
- Unregulated products. A 2026 review of injectable “biohacking” peptides lists BPC-157 among compounds without an established human safety profile and names contamination and manufacturing impurities among the real risks.[15]
A 2026 review of its pharmaceutical development adds that no pharmaceutical grade formulation with validated pharmacokinetics exists yet, which is a barrier to rigorous clinical trials and to building an evidence base.[16]
FDA Approval: Is BPC-157 Approved, and Are Peptides Legal in the UAE?
- FDA approval. No. BPC-157 is not an FDA-approved drug and not an approved treatment option for any condition; FDA reports no approved product in any country.[1]
- Compounding pharmacies. On July 23, 2026 FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 for ulcerative colitis to the list compounding pharmacies may use, against the advice of FDA’s reviewers. The vote is advisory and non-binding.[17][1]
- Sport. The World Anti-Doping Agency has named BPC-157 in class S0 (non-approved substances) since 2022, and the 2027 List keeps it there. It is prohibited at all times.[18][19]
- UAE. BPC-157 is not a registered medicine. Remy Research sells it for in-vitro laboratory research only, not for human or veterinary use. For the wider question of whether peptides are legal in the UAE, see are peptides legal in the UAE and Dubai.
BPC-157 vs Other Anti-Inflammatory and Repair Peptides
BPC-157 is often grouped with TB-500 and GHK-Cu as “healing” peptides. They are different molecules with different evidence: TB-500 is a seven-amino-acid fragment of thymosin beta-4, and GHK-Cu is a copper-binding tripeptide studied mainly in skin. None has an approved treatment use for injuries. For side-by-side detail, see BPC-157 vs TB-500 and KPV vs BPC-157 vs GHK-Cu.
What the Current Evidence Does Not Yet Give You
- Proof of benefit in people. No controlled human clinical trial has shown that BPC-157 helps any condition.[1][2]
- A human safety profile. Rare and long-term effects cannot be seen in a few dozen participants.[2]
- Independent replication. Much of the animal work comes from a narrow group of laboratories.[6][7]
- A standard formulation. No validated pharmaceutical-grade product exists to test in trials.[16]
These gaps are not arguments against studying BPC-157. They are arguments against overselling it.
BPC-157 for Laboratory Research
Remy Research supplies BPC-157 for in-vitro research in three formats: the BPC-157 10mg research vial, the BPC-157 20mg pen and the Genovare BPC-157 25mg AQ pen. Each product page carries its batch testing details. For the full mechanism and preclinical record, read the BPC-157 research review; for handling, see BPC-157 storage and stability.
Our Research Standards
This article prioritizes primary literature, trial registries and regulator records, and keeps animal and human evidence apart. Where the human record is thin, we say so directly. No therapeutic, dosing or administration guidance is given. Read our editorial policy →
BPC-157 Benefits and Side Effects FAQ
What are the benefits of BPC-157?
What are the side effects of BPC-157?
There is no reliable list, because so few people have been studied. FDA found three adverse-event reports (injection-site redness and swelling, shortness of breath, and skin darkening with a combined product), none clearly attributable to BPC-157, and flagged possible immune reactions and impurities.[1]
Is BPC-157 safe?
Is BPC-157 hard on the kidneys?
No study has shown kidney harm, but there are no long-term human data either. In a two-person intravenous pilot, the kidney markers tested did not change.[10]
Is BPC-157 FDA approved?
Has BPC-157 been tested in human clinical trials?
Is it safe to combine BPC-157 with multiple peptides?
Is BPC-157 banned in sport?
Is BPC-157 a dietary supplement?
No. It is a synthetic peptide with no approved medical use and is not a legal dietary ingredient. Remy Research supplies it for in-vitro laboratory research only.
Sources
- U.S. Food and Drug Administration. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), dated May 11, 2026. Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026. fda.gov/media/193343 ↩
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). Published online October 8, 2026. doi: 10.52628/92.3.15837 · PMID: 42885452 ↩
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi: 10.2174/138161211796196954 · PMID: 21548867 ↩
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi: 10.1007/s00109-016-1488-y · PMID: 27847966 ↩
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi: 10.1152/japplphysiol.00945.2010 · PMID: 21030672 ↩
- Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026 (online August 11, 2026). doi: 10.1177/03635465261464420 · PMID: 42578445 ↩
- Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026;27(18):8344. doi: 10.3390/ijms27188344 · PMID: 42794771 ↩
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435 ↩
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID: 39325560 ↩
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143 ↩
- ClinicalTrials.gov. NCT07803250: Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (University of Arkansas). Status “not yet recruiting”, estimated start January 2027; record checked October 27, 2026. clinicaltrials.gov/study/NCT07803250 ↩
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi: 10.1016/j.yrtph.2020.104665 · PMID: 32334036 ↩
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi: 10.3389/fphar.2022.1026182 · PMID: 36588717 ↩
- Palat LN. Decoding the peptide craze: UAE experts explain the risky injectable wellness trend and what science says. Gulf News, May 11, 2026. gulfnews.com ↩
- Moiz A, O’Keefe EL, O’Keefe JH. Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs. Mo Med. 2026;123(4):337-343. PMID: 42757290 ↩
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi: 10.3390/pharmaceutics18050625 · PMID: 42198317 ↩
- Choi J. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. The Hill, July 23, 2026. thehill.com ↩
- World Anti-Doping Agency. WADA’s 2022 Prohibited List now in force (BPC-157 first named in class S0). January 1, 2022. wada-ama.org ↩
- World Anti-Doping Agency. WADA publishes 2027 Prohibited List (S0 Non-approved substances names BPC-157; in force January 1, 2027). September 21, 2026. wada-ama.org ↩
For catalog details, see the BPC-157 10mg research vial, the BPC-157 20mg pen and the Genovare BPC-157 25mg AQ pen. For editorial standards, continue to the editorial policy.